USE OF INTRAVENOUS LIPID EMULSION THERAPY IN A CASE OF ATOMOXETINE (STRATTERA (R)) TOXICITY

Basit Öğe Kaydı
dc.authorwosidGun, Emrah/AAO-8819-2021
dc.contributor.authorGun, Emrah
dc.contributor.authorKocabay, Kenan
dc.date.accessioned2021-12-01T18:47:15Z
dc.date.available2021-12-01T18:47:15Z
dc.date.issued2020
dc.department[Belirlenecek]en_US
dc.description.abstractBackground: Clinical manifestations after overdose of atomoxetine are generally mild. However, it may have moderate or severe toxic effects such as drowsiness, agitation, hyperactivity, tremors, tachycardia, hyperreflexia, hypertension, and seizures. The duration of symptoms is usually short, lasting < 24 h. We report a case of atomoxetine toxicity, which can be considered of value, as intravenous lipid emulsion therapy has not been previously reported in an overdose of atomoxetine. This is a case of atomoxetine toxicity initially thought to be sertraline. Case Report: The case is presented of a 14-year-old girl with seizures following an overdose of atomoxetine who was unresponsive to intravenous benzodiazepine, but showed an improvement in overall condition after intravenous lipid emulsion therapy. To the best of our knowledge, there has been no previous report in the literature of the use of intravenous lipid therapy after atomoxetine overdose. Why Should an Emergency Physician Be Aware of This?: Intravenous lipid emulsion therapy is used as an alternative therapy in acute lipophilic drug intoxications. In children and adults, there is an increase in the use of intravenous lipid emulsion therapy in the life-threatening toxicity of many lipophilic drugs. Intravenous lipid emulsion therapy provides 'lipid sink' for toxic, lipophilic drugs, thereby effectively keeping toxic and lipophilic drugs out of the periphery. Intravenous lipid emulsion therapy reduces the distribution of lipophilic drugs. (C) 2020 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.jemermed.2020.04.042
dc.identifier.endpageE49en_US
dc.identifier.issn0736-4679
dc.identifier.issn1090-1280
dc.identifier.issue2en_US
dc.identifier.pmid32505448en_US
dc.identifier.scopus2-s2.0-85085772010en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpageE47en_US
dc.identifier.urihttps://doi.org/10.1016/j.jemermed.2020.04.042
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10205
dc.identifier.volume59en_US
dc.identifier.wosWOS:000572677200003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal Of Emergency Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectatomoxetineen_US
dc.subjectchilden_US
dc.subjectintoxicationen_US
dc.subjectintravenous lipid emulsionen_US
dc.subjectsuicideen_US
dc.subjectOverdoseen_US
dc.subjectDrugsen_US
dc.titleUSE OF INTRAVENOUS LIPID EMULSION THERAPY IN A CASE OF ATOMOXETINE (STRATTERA (R)) TOXICITYen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
10205.pdf
Boyut:
109.09 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu